PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY), a biopharmaceutical company, and Takeda Pharmaceutical Company Limited today announced that they were honored with the Allicense 2007 Breakthrough Alliance Award for their exclusive global agreement to develop and commercialize Hematide™, Affymax’s lead product candidate, for the treatment of anemia. The award, given for the best and most innovative practices in drafting and negotiating alliances between biotechnology and pharmaceutical companies, is sponsored by Recombinant Capital and was presented at the Allicense 2007 conference in San Francisco.
